Danaher Co. (NYSE:DHR) Shares Bought by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lifted its position in shares of Danaher Co. (NYSE:DHR) by 8.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 11,434 shares of the conglomerate’s stock after buying an additional 926 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Danaher were worth $2,648,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC boosted its position in shares of Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after acquiring an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. grew its holdings in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the period. Cercano Management LLC increased its position in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares during the period. Finally, Parkside Financial Bank & Trust lifted its position in Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after buying an additional 142 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $254.13 on Tuesday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock has a market cap of $188.23 billion, a PE ratio of 43.07, a price-to-earnings-growth ratio of 3.90 and a beta of 0.85. The company’s 50-day moving average price is $253.68 and its two-hundred day moving average price is $244.68.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period last year, the firm posted $2.36 earnings per share. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Monday. Robert W. Baird boosted their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Barclays lifted their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Citigroup upped their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $269.29.

Insider Activity at Danaher

In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,783 shares of company stock worth $37,536,717. 10.90% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.